8 / 22
EAGLE: phase 3 in 2
nd
line
R/M HNC
(oral, oropharynx, larynx, hypopharynx)
At least 1 measurable lesions
per RECIST v1.1
Failure of 1 platinum-based
CT in the R/M setting
PDL1 independent
(+/- 80% >6m Platino)
Durvalumab
Durvalumab + Tremelilumab
SOC
Unfortunately, the trial
did not meet the primary endpoint for OS
for
Imfinzi
monotherapy
or
Imfinzi
plus tremelimumab combination therapy compared with SoC in patients with R/M
HNSCC who progressed following platinum-based chemotherapy, regardless of PD-L1 expression.
• Cetuximab
• MTX
• 5-FU/Capecitabina
• Taxol/Taxotere w
?
Selección
pacientes